Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Syneos Health, Inc. is a leading biopharmaceutical solutions organization that provides integrated biopharmaceutical solutions to help clients accelerate product development and commercialization. With a strong presence in North America and Europe, Syneos leverages its unique combination of clinical and commercial expertise to drive efficiencies in the drug development process, particularly in the areas of clinical trials and regulatory strategy.
Syneos Health generates revenue primarily through its Clinical Solutions segment, which offers services such as clinical trial management and regulatory consulting. The Commercial Solutions segment provides marketing, sales, and access solutions. The company's competitive advantage lies in its integrated approach, allowing for streamlined processes and reduced time to market for clients' products.
Changes in biopharmaceutical R&D spending trends
Regulatory approvals impacting client projects
Partnership announcements with major pharmaceutical companies
Market demand for outsourced clinical and commercial services
Regulatory changes that could impact drug approval processes
Technological disruption in clinical trial methodologies
Intensifying competition from other contract research organizations (CROs)
Emergence of in-house capabilities among pharmaceutical companies
Moderate debt levels may limit financial flexibility in downturns
Potential pension obligations affecting cash flow
moderate - The demand for clinical and commercial services is somewhat correlated with overall healthcare spending, which can be influenced by GDP growth.
Higher interest rates can increase financing costs for clients, potentially slowing down R&D investments and impacting Syneos' revenue growth. Additionally, higher rates may compress valuation multiples in the sector.
minimal - Syneos Health operates with a manageable debt level, and its revenue model is not heavily reliant on credit.
growth - Investors are likely attracted to Syneos for its potential to capture market share in the growing outsourced clinical services market.
moderate - The stock has shown fluctuations in response to earnings reports and industry developments, with a beta around 1.2.